Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00780962 · ClinicalTrials.gov registry record · Phase 2
N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients
A Phase 2 study of Radiocontrast Nephropathy, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 399
- Enrollment target
- 1
- Study location
NCT00780962: Completed Phase 2 study of Radiocontrast Nephropathy, sponsored by Beth Israel Deaconess Medical Center.
NCT00780962 is a Phase 2 study of Radiocontrast Nephropathy that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 399 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (200% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00780962, a Phase 2 study of Radiocontrast Nephropathy, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 399 participants
- Enrollment target
- 1
- Study location
Study Summary
Multiple agents have been studied to prevent radiocontrast nephropathy. One of these agents is N-Acetylcysteine. Previous trials to assess N-Acetylcysteine's efficacy in the prevention of contrast nephropathy have been promising. However, previous studies have limited applicability to the Emergency Department (ED) patient population for two reasons: * 1\) Many of the pretreatment strategies employed in these studies take several hours or even days to perform, which is not feasible in acutely ill ED patients. * 2\) Most of these studies were conducted in patients undergoing cardiac catheterization. This may be a very different population than patients in the ED undergoing abdominal or chest computed tomography. The investigators wish to study the efficacy of N-acetylcysteine as an agent to prevent radiocontrast nephropathy in ED patients undergoing computerized tomography. The investigators propose a randomized, double-blind, controlled trial comparing saline hydration plus N-acetylcysteine versus saline hydration alone. The hypothesis of this study is that N-acetylcysteine with normal saline will be more effective than saline alone in the prevention of radiocontrast nephropathy.
Primary Outcome
Contrast-induced nephropathy was defined as an increase in serum creatinine level of greater than or equal to 0.5 mg/dL or an increase of 25% above baseline. The primary outcome was measured by the change in serum creatinine level from the pre-radiocontrast baseline to the serum creatinine level measured 48 to 72 hours after radiocontrast administration.
Conditions Studied
Interventions
- DRUG N-Acetylcysteine (NAC)
- DRUG 0.9% Sodium-chloride
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 399 participants |
| Start Date | 2007-10-16 |
| Est. Completion | 2010-08-09 |
| Phase | Phase 2 |
What the finished NCT00780962 record still lists
NCT00780962 is an interventional study that assigns participants to a tested intervention. The registered 399 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (200% higher).
The record links to 1 condition, with Radiocontrast Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which N-Acetylcysteine (NAC) is the first listed.
NCT00780962 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00780962 about?
NCT00780962 is a clinical study titled "N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients". Multiple agents have been studied to prevent radiocontrast nephropathy. One of these agents is N-Acetylcysteine. Previous trials to assess N-Acetylcysteine's efficacy in the prevention of contrast nephropathy have been promising. However, previous studies have limited applicability to the Emergency ...
What is the current status of trial NCT00780962?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 399 participants. The study started on 2007-10-16. Estimated completion is 2010-08-09.
What conditions does trial NCT00780962 study?
This clinical trial studies the following conditions: Radiocontrast Nephropathy.
What interventions are being tested in trial NCT00780962?
The interventions under investigation include: N-Acetylcysteine (NAC) (DRUG), 0.9% Sodium-chloride (DRUG).
Who is sponsoring clinical trial NCT00780962?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00780962 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00780962's enrollment target sits among peer trials
399 103rd of 2000 higher than 1,898 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03165734 · 399 participants · Phase 3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- NCT05022862 · 399 participants · NA
Economic Incentives and vDOT for Latent Tuberculosis Infection
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI